- Home
- KPRX vs CLRO Comparison
KPRX vs CLRO Comparison
Compare KPRX & CLRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPRX | CLRO |
|---|---|---|
| Founded | 1998 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 9.2M |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KPRX | CLRO |
|---|---|---|
| Price | $2.47 | $3.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.4K | ★ 691.1K |
| Earning Date | 11-06-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $46,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.59 |
| 52 Week Low | $1.76 | $2.71 |
| 52 Week High | $2.91 | $16.50 |
Technical Indicators
Market Signals| Indicator | KPRX | CLRO |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 37.92 |
| Support Level | $2.45 | $3.18 |
| Resistance Level | $2.61 | $3.88 |
| Average True Range (ATR) | 0.05 | 0.63 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 4.55 | 0.73 |
Price Performance
Historical ComparisonAbout KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About CLRO ClearOne Inc. (DE)
ClearOne Inc is currently engaged in activities that consist solely of fulfilling warranty and technical support obligations on legacy products, evaluating potential Strategic Transactions, managing and liquidating remaining assets of the company's legacy operating business, collecting accounts receivable and recovering prepaid assets, satisfying outstanding liabilities, and maintaining public-company compliance.